
United Therapeutics (UTHR) Stock Forecast & Price Target
United Therapeutics (UTHR) Analyst Ratings
Bulls say
United Therapeutics is poised for long-term growth due to its strong focus on the prostacyclin pathway for treating PAH and its market-leading position in this disease space. The company's diverse portfolio of commercialized products and ongoing research in new indications such as IPF and PH-ILD, as well as its plans to launch the treprostinil soft mist inhaler, show potential for continued success. Furthermore, the company's impressive financial results and favorable response from key opinion leaders in the field of PAH bode well for its future growth and positioning as a key player in the PAH market.
Bears say
United Therapeutics is facing potential limitations in its market expansion plans, as discussions around expanding Tyvaso into IPF are influenced by uncertainty around the drug's antifibrotic activity versus its treatment of accompanying pulmonary vascular disease. Additionally, while there is potential for Tyvaso to address a broad IPF treatment role, the company faces significant competition in this market as well as potential regulatory challenges. Given these factors, the company's stock may struggle in the long term.
This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
United Therapeutics (UTHR) Analyst Forecast & Price Prediction
Start investing in United Therapeutics (UTHR)
Order type
Buy in
Order amount
Est. shares
0 shares